1.84
+0(+0.00%)
Currency In USD
| Previous Close | 1.84 |
| Open | 1.82 |
| Day High | 1.85 |
| Day Low | 1.77 |
| 52-Week High | 3.84 |
| 52-Week Low | 1.58 |
| Volume | 794,257 |
| Average Volume | 924,740 |
| Market Cap | 31.81M |
| PE | -0.8 |
| EPS | -2.31 |
| Moving Average 50 Days | 2.22 |
| Moving Average 200 Days | 2.68 |
| Change | 0 |
If you invested $1000 in NRx Pharmaceuticals, Inc. (NRXP) since IPO date, it would be worth $19.17 as of February 21, 2026 at a share price of $1.84. Whereas If you bought $1000 worth of NRx Pharmaceuticals, Inc. (NRXP) shares 5 years ago, it would be worth $5.1 as of February 21, 2026 at a share price of $1.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
GlobeNewswire Inc.
Feb 17, 2026 12:00 PM GMT
NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER)Oral guidance received at the meeting provides a p
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
GlobeNewswire Inc.
Jan 16, 2026 12:03 PM GMT
WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
GlobeNewswire Inc.
Jan 14, 2026 12:03 PM GMT
NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance, is supplied and generated by